EIC Summit 25 Networking Platform

2 – 3 Apr 2025 | Brussels, Belgium

InvestmentUpdated on 24 March 2025

Serie A

Nathalie Donne

CEO at ErVimmune

Lyon, France

About

Our current Series A target is €10M. To date, €8.5M are already secured from the European Investment Bank (€5M), Seventure (€2.5M), and SPRIM (€0.75M to €1M).

The proceeds from this Series A round will fund our pharmaceutical development in collaboration with our CDMO partner, and enable our First-in-Human trial. This study aims to evaluate the safety and efficacy of our durg candidate in combination with an immune checkpoint inhibitor, such as pembrolizumab, in patients with relapsed/refractory advanced or metastatic TNBC.

We are eager to finalize this Series A and move forward to the clinic as soon as possible!

Organisation

ErVimmune

Start-ups and SMEs

Lyon, France

Similar opportunities

  • Investment

    High Valuation Deal: A €1M SAFE/convertible with a €10M cap converts to 10% equity

    • Others
    • Startup
    • Possible exit

    Dima Arvo

    CEO/CTO/CPO at ARVO OY

    Espoo, Finland

  • Investment

    Series A Round

    • Others
    • Startup
    • Growth and Establishment
    • Climate & Environmental Tech
    • Advanced Manufacturing & Advanced Materials

    Christophe Berlo

    CFO at Resortecs / regeneration BV

    Brussels, Belgium

  • Investment

    Series A

    • Energy
    • Expansion
    • AI, Data & ICT
    • Speed and Development
    • Growth and Establishment
    • Climate & Environmental Tech
    • Quantum, Advanced Computing & Semiconductors

    Lovisa Urheim

    Head of Strategic Initiatives at Plexigrid

    Stockholm, Sweden